Eric A. Voight
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric A. Voight has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Nathaniel Greszler
Research & Development, AbbVie, Inc., 1 N Waukegan Rd, North Chicago, Illinois 60064, United States
9 shared publications - Huw Davies
Emory University
5 shared publications Bhadra Shelat
Research & Development, AbbVie, Inc., 1 N Waukegan Rd, North Chicago, Illinois 60064, United States
3 shared publicationsBo Wei
Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, Georgia 30322, United States
3 shared publications- Brian S. Brown
AbbVie Bay Area , 1000 Gateway Boulevard
3 shared publications - David A. DeGoey
Research and Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States
3 shared publications
Latest Publications
- 13 November 2026
- Published by American Chemical Society (ACS) in Organic Letters
Asymmetric Synthesis of a Small Molecule Inhibitor of TNFα via Enantioenriched 4-Substituted Tetrahydroisoquinolines
An improved decagram-scale enabling asymmetric synthesis of a lead small molecule inhibitor of TNFα is described. An overall >15-fold improvement in yield compared to the original route was accomplished through the development of a new chromatography-free enantioselective sequence that delivered >20 g of the target compound. Highlights of the new route include an efficient Parham cyclization that rapidly afforded hectagram quantities of a key dihydroisoquinolone, an uncommon asymmetric synthesis of 4-hydroxy and 4-amino tetrahydroisoquinoline intermediates, and improved Cu-free access to the unique heterocycle-rich pentacyclic scaffold.
- 13 November 2026
- Published by American Chemical Society (ACS) in Organic Letters
Asymmetric Synthesis of a Small Molecule Inhibitor of TNFα via Enantioenriched 4-Substituted Tetrahydroisoquinolines
An improved decagram-scale enabling asymmetric synthesis of a lead small molecule inhibitor of TNFα is described. An overall >15-fold improvement in yield compared to the original route was accomplished through the development of a new chromatography-free enantioselective sequence that delivered >20 g of the target compound. Highlights of the new route include an efficient Parham cyclization that rapidly afforded hectagram quantities of a key dihydroisoquinolone, an uncommon asymmetric synthesis of 4-hydroxy and 4-amino tetrahydroisoquinoline intermediates, and improved Cu-free access to the unique heterocycle-rich pentacyclic scaffold.
- 9 October 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (41) , 44901-44909
General Asymmetric Synthesis of Noncanonical Amino Acids
Noncanonical amino acids (ncAAs) are valuable building blocks with applications spanning biology, material science, and pharmaceutical development. The concise asymmetric syntheses of diverse ncAAs from fundamental building blocks would be highly enabling, yet methods to achieve this goal are limited. Herein, we present a general strategy for the asymmetric synthesis of ncAAs from ubiquitous carboxylic acids involving transformation to α-ketoesters followed by a biocatalytic lipase hydrolysis-transamination cascade. The process features a broad scope, delivering ncAAs from carboxylic acids with diverse cyclic frameworks, multiple stereogenic centers, and even oligopeptides. Either ncAA enantiomer with various chain lengths is easily accessed upon simple modification of the sequence, which may also be performed in a telescoped, one-pot fashion. This approach combines the power of organic synthesis and biocatalysis to enable the general asymmetric synthesis of ncAAs.
- 9 October 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (41) , 44901-44909
General Asymmetric Synthesis of Noncanonical Amino Acids
Noncanonical amino acids (ncAAs) are valuable building blocks with applications spanning biology, material science, and pharmaceutical development. The concise asymmetric syntheses of diverse ncAAs from fundamental building blocks would be highly enabling, yet methods to achieve this goal are limited. Herein, we present a general strategy for the asymmetric synthesis of ncAAs from ubiquitous carboxylic acids involving transformation to α-ketoesters followed by a biocatalytic lipase hydrolysis-transamination cascade. The process features a broad scope, delivering ncAAs from carboxylic acids with diverse cyclic frameworks, multiple stereogenic centers, and even oligopeptides. Either ncAA enantiomer with various chain lengths is easily accessed upon simple modification of the sequence, which may also be performed in a telescoped, one-pot fashion. This approach combines the power of organic synthesis and biocatalysis to enable the general asymmetric synthesis of ncAAs.
- 25 July 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (30) , 31931-31939
Catalytic Asymmetric Metallocyclopropanation Reactions Using Chloroform as a Carbyne Equivalent
Stereochemically complex, sp3-rich rings have attracted significant interest in drug discovery because of their ability to mitigate the physicochemical liabilities associated with flat aromatic rings. Cyclopropanes are attractive targets in this regard because they have unique three-dimensional structures and are resistant to metabolism. Numerous catalytic enantioselective alkene cyclopropanation reactions have been developed using carbene precursors. However, most of these methods use energetic reagents and are restricted to specific classes of resonance-stabilized carbenes. Here, we report a catalytic asymmetric cyclopropanation reaction using chloroform as a methylidyne equivalent and Zn as a stoichiometric reductant. The products are metallocyclopropanes that can be further functionalized in a telescoped process to yield halo-, aryl-, allyl-, alkynyl-, vinyl-, and other substituted cyclopropanes in highly enantioenriched form. A notable feature of the reaction is the high degree of cis diastereoselectivity, which is controlled by the large N-aryl substituent of the ligand. Application in the parallel synthesis of enantioenriched 1,2-diarylcyclopropanes bearing pharmaceutically relevant heterocycles is demonstrated.
- 25 July 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (30) , 31931-31939
Catalytic Asymmetric Metallocyclopropanation Reactions Using Chloroform as a Carbyne Equivalent
Stereochemically complex, sp3-rich rings have attracted significant interest in drug discovery because of their ability to mitigate the physicochemical liabilities associated with flat aromatic rings. Cyclopropanes are attractive targets in this regard because they have unique three-dimensional structures and are resistant to metabolism. Numerous catalytic enantioselective alkene cyclopropanation reactions have been developed using carbene precursors. However, most of these methods use energetic reagents and are restricted to specific classes of resonance-stabilized carbenes. Here, we report a catalytic asymmetric cyclopropanation reaction using chloroform as a methylidyne equivalent and Zn as a stoichiometric reductant. The products are metallocyclopropanes that can be further functionalized in a telescoped process to yield halo-, aryl-, allyl-, alkynyl-, vinyl-, and other substituted cyclopropanes in highly enantioenriched form. A notable feature of the reaction is the high degree of cis diastereoselectivity, which is controlled by the large N-aryl substituent of the ligand. Application in the parallel synthesis of enantioenriched 1,2-diarylcyclopropanes bearing pharmaceutically relevant heterocycles is demonstrated.
- 19 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13788-13806
Discovery of Fosigotifator, a Potent eIF2B Activator with Desired Properties for Human Studies
The integrated stress response (ISR) is a highly conserved cellular pathway triggered by a variety of insults, reducing protein synthesis and inducing ATF4, leading to broadly remodeling the cellular transcriptome and metabolome. ISRIB, 1, the first identified eIF2B activator, attenuates the ISR restoring protein synthesis, but its poor solubility limits absorption and advancement. To improve drug-like properties, we explored replacements for both the cyclohexyl core and side chains of ISRIB. This effort initially led to truncated analogue, 2BAct, 13, which demonstrated improved solubility relative to 1; however, cardiovascular effects in higher species limited its progression into the clinic. Potent analogue 9 was identified with significantly improved solubility vs 1 but was still projected to have solubility-limited absorption. A prodrug campaign resulted in the identification of compound 26 (fosigotifator), which exhibited significantly improved solubility and is currently being investigated in the clinic.
- 19 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13788-13806
Discovery of Fosigotifator, a Potent eIF2B Activator with Desired Properties for Human Studies
The integrated stress response (ISR) is a highly conserved cellular pathway triggered by a variety of insults, reducing protein synthesis and inducing ATF4, leading to broadly remodeling the cellular transcriptome and metabolome. ISRIB, 1, the first identified eIF2B activator, attenuates the ISR restoring protein synthesis, but its poor solubility limits absorption and advancement. To improve drug-like properties, we explored replacements for both the cyclohexyl core and side chains of ISRIB. This effort initially led to truncated analogue, 2BAct, 13, which demonstrated improved solubility relative to 1; however, cardiovascular effects in higher species limited its progression into the clinic. Potent analogue 9 was identified with significantly improved solubility vs 1 but was still projected to have solubility-limited absorption. A prodrug campaign resulted in the identification of compound 26 (fosigotifator), which exhibited significantly improved solubility and is currently being investigated in the clinic.
- 20 January 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (2) , 257-258
The Value of Academic and Industrial Collaborations in Drug Discovery
- 20 January 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (2) , 257-258
The Value of Academic and Industrial Collaborations in Drug Discovery
- Open Access
- 13 October 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (11) , 2130-2137
Academic–Industrial Collaboration in Synthesis with Real-Time Impact in Medicinal Chemistry: Discovery of Cystic Fibrosis C2 Corrector ABBV-602
This article highlights synergistic real-time interactions between academic and industrial groups that drove innovations in both medicinal chemistry and catalysis. An AbbVie medicinal chemistry team had identified a promising series of trisubstituted cyclopropanes during a drug discovery campaign focused on developing CFTR C2 correctors for the treatment of cystic fibrosis. However, this unique chemical space was challenging to efficiently explore due to known limitations with previously established cyclopropanation reaction conditions. By expanding upon an existing precompetitive relationship with the Davies group at Emory University who are pioneers in development of methods for highly diastereo- and enantioselective cyclopropanations, a joint industry-academia team collaborated to discover a unique catalyst-additive system for this challenging transformation that had a broad and pharmaceutically relevant substrate scope. The optimized method was immediately applied to accelerate medicinal chemistry progress in the series, leading to the identification of novel CFTR corrector ABBV-602. Finally, a flow procedure was developed for generating the carbene precursor which enabled the reaction to be carried out on kilogram scale.
- 13 October 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (11) , 2130-2137
Open AccessAcademic–Industrial Collaboration in Synthesis with Real-Time Impact in Medicinal Chemistry: Discovery of Cystic Fibrosis C2 Corrector ABBV-602
This article highlights synergistic real-time interactions between academic and industrial groups that drove innovations in both medicinal chemistry and catalysis. An AbbVie medicinal chemistry team had identified a promising series of trisubstituted cyclopropanes during a drug discovery campaign focused on developing CFTR C2 correctors for the treatment of cystic fibrosis. However, this unique chemical space was challenging to efficiently explore due to known limitations with previously established cyclopropanation reaction conditions. By expanding upon an existing precompetitive relationship with the Davies group at Emory University who are pioneers in development of methods for highly diastereo- and enantioselective cyclopropanations, a joint industry-academia team collaborated to discover a unique catalyst-additive system for this challenging transformation that had a broad and pharmaceutically relevant substrate scope. The optimized method was immediately applied to accelerate medicinal chemistry progress in the series, leading to the identification of novel CFTR corrector ABBV-602. Finally, a flow procedure was developed for generating the carbene precursor which enabled the reaction to be carried out on kilogram scale.
- 17 June 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (33) , 29722-29731
Monocyclic Azetidines via a Visible-Light-Mediated Aza Paternò-Büchi Reaction of Ketone-Derived Sulfonylimines
The recent rise in popularity of azetidines in pharmaceutical chemistry has inspired the development of visible-light-mediated aza Paternò-Büchi reactions as direct transformations to form these desirable products. Despite these advancements, successful reports of accessing monocyclic azetidines from acyclic imines remain scarce. Here, we report a visible-light-mediated aza Paternò-Büchi reaction of acyclic ketone-derived sulfonylimines, which are previously unexplored substrates in this transformation, with activated alkenes (i.e., styrenes and dienes) to form 2,2-disubstituted monocyclic azetidines that can be further modified to reveal free N-H azetidines. Computational and experimental mechanistic studies reveal that in contrast to aldehyde-derived oximes, the use of ketone-derived sulfonylimines enables tuning of the reaction mechanism to favor initial formation of the C-N rather than C-C bond, thus enabling access to 2,2-disubstituted monocyclic azetidine scaffolds.
- 17 June 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (33) , 29722-29731
Monocyclic Azetidines via a Visible-Light-Mediated Aza Paternò-Büchi Reaction of Ketone-Derived Sulfonylimines
The recent rise in popularity of azetidines in pharmaceutical chemistry has inspired the development of visible-light-mediated aza Paternò-Büchi reactions as direct transformations to form these desirable products. Despite these advancements, successful reports of accessing monocyclic azetidines from acyclic imines remain scarce. Here, we report a visible-light-mediated aza Paternò-Büchi reaction of acyclic ketone-derived sulfonylimines, which are previously unexplored substrates in this transformation, with activated alkenes (i.e., styrenes and dienes) to form 2,2-disubstituted monocyclic azetidines that can be further modified to reveal free N-H azetidines. Computational and experimental mechanistic studies reveal that in contrast to aldehyde-derived oximes, the use of ketone-derived sulfonylimines enables tuning of the reaction mechanism to favor initial formation of the C-N rather than C-C bond, thus enabling access to 2,2-disubstituted monocyclic azetidine scaffolds.
- 20 November 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (48) , 32919-32924
Homologation of Carboxylic Acids Using a Radical-Polar Conjunctive Reagent
Homologations of organic molecules that add a carbon atom to the substrate are useful in drug discovery to access compounds with improved properties that otherwise present a synthetic challenge. Carboxylic acids are present in many bioactive molecules and are widely available building blocks for chemical synthesis, yet their direct homologation is unknown. This valuable transformation currently necessitates implementation of multistep processes that require the use of carboxylic acid derivatives rather than the native substrates, and commonly involves highly reactive and toxic reagents. Herein, we report the first one-step homologation directly from native carboxylic acids using a novel, bench-stable (1-phosphoryl)vinyl sulfonate reagent under mild conditions. This strategy was applied to a wide range of aliphatic carboxylic acid building blocks and biologically relevant complex molecules to access an array of ester, amide, and carboxylic acid homologues in a single step. The (1-phosphoryl)vinyl sulfonate reagent participates in complementary homologation protocols featuring either radical-chain transfer or organic photoredox catalysis and introduces a new synthon, the distonic acylium radical, for molecular diversification. We anticipate this strategy, which addresses a long-standing challenge in organic synthesis, will expedite drug discovery by enabling the rapid synthesis of diversified homologues.
- 20 November 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (48) , 32919-32924
Homologation of Carboxylic Acids Using a Radical-Polar Conjunctive Reagent
Homologations of organic molecules that add a carbon atom to the substrate are useful in drug discovery to access compounds with improved properties that otherwise present a synthetic challenge. Carboxylic acids are present in many bioactive molecules and are widely available building blocks for chemical synthesis, yet their direct homologation is unknown. This valuable transformation currently necessitates implementation of multistep processes that require the use of carboxylic acid derivatives rather than the native substrates, and commonly involves highly reactive and toxic reagents. Herein, we report the first one-step homologation directly from native carboxylic acids using a novel, bench-stable (1-phosphoryl)vinyl sulfonate reagent under mild conditions. This strategy was applied to a wide range of aliphatic carboxylic acid building blocks and biologically relevant complex molecules to access an array of ester, amide, and carboxylic acid homologues in a single step. The (1-phosphoryl)vinyl sulfonate reagent participates in complementary homologation protocols featuring either radical-chain transfer or organic photoredox catalysis and introduces a new synthon, the distonic acylium radical, for molecular diversification. We anticipate this strategy, which addresses a long-standing challenge in organic synthesis, will expedite drug discovery by enabling the rapid synthesis of diversified homologues.
- 17 September 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (10) , 1651
Call for Papers: Academic and Industrial Collaborations in Drug Discovery
- 17 September 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (10) , 1651
Call for Papers: Academic and Industrial Collaborations in Drug Discovery